header-logo header-logo

06 November 2015
Issue: 7675 / Categories: Case law , Law digest , In Court
printer mail-detail

Patent

Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG [2015] EWHC 2963 (Pat), [2015] All ER (D) 214 (Oct)

The Chancery Division held that an application brought by the defendant pharmaceutical company, Boehringer Ingelheim Pharma GmbH & Co KG, to introduce new claims to a patent dispute would be dismissed, where the proposed use of a drug, to be used in a dry powder inhaler for the delivery of tiotropium bromide to the lung of a patient suffering from chronic obstructive pulmonary disease or asthma, was obvious and the new claims revealed no inventive step.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

EIP—Stuart Malcolm

EIP—Stuart Malcolm

EIP strengthens Commercial practice with a new partner

Ellisons—Francesca Brown

Ellisons—Francesca Brown

Ellisons welcomes Francesca Brown to Family team

Shakespeare Martineau—Marie Bourke

Shakespeare Martineau—Marie Bourke

Shakespeare Martineau strengthens Sheffield regulatory practice with new hires

NEWS
A wide-ranging Civil Way column highlights developments from insolvency procedure to employment law, but one case stands out for its lessons on bankruptcy, family homes and digital communications
A sprawling Intellectual Property Office battle between House of Fraser and Frasers Property has delivered a masterclass in modern trade mark law
Courts in England and Wales and Singapore are increasingly confronting complex disputes over international child relocation as families become more globally mobile
The government’s long-awaited family law reform consultation could mark a turning point for domestic abuse victims navigating financial remedy proceedings, but significant challenges remain
A new commercial court pilot giving the public access to documents used in hearings, including expert reports, is raising difficult questions about transparency and privacy
back-to-top-scroll